Researchers say the gut microbiome may be a viable targetable biomarker to improve immunotherapy responses in those with glioblastoma and a range of other cancers.
Researchers are currently recruiting patients for a Phase 1 trial of a new immunotherapy treatment for glioblastoma brain cancer.
Disabling the CD161 pathway restores the T-cell's ability to attack gliomas and extends lifespan in animal models of brain cancer.
Treating coronavirus patients with alpha-blockers may help prevent the cytokine storm associated with severe COVID-19 infection. Alpha-blockers interfere with the cell signaling that triggers cytokine storms. Mice with bacterial infections that were treated with alpha-blockers experienced reduced cytokine storms and decreased death rates.
Administering medulloblastoma specific CAR T cells into the cerebrospinal fluid was more effective than administering via the blood.
Glioma patients whose tumors were hypermutated showed no significant benefit when treated with checkpoint blockers.
Clinical trials for a preventative treatment for dementia was successful in mouse models. Researchers say human trials will begin in two years.
Those with a higher body mass index who are given atezolizumab to treat cancer have an improved rate of survival, a new study reveals.
Researchers report administering immunotherapy treatment prior to surgery for those with recurring glioblastoma brain cancer is more effective that using the treatment after surgery.
Researchers report a clinical trial of a personalized vaccine that targets glioblastoma brain cancer has successfully improved survival rates for patients.
A new immunotherapy treatment for ALS patients is not only safe, but can also help slow the progression of the disease, researchers report.
Johns Hopkins researchers utilize AI technology to create a map which compares different cellular receptors on the surface of T-cells.
